TY - JOUR
T1 - Clinical results of implant placement in resorbed ridges using simultaneous guided bone regeneration
T2 - a multicenter case series
AU - Konstantinidis, Ioannis
AU - Kumar, Tarun
AU - Kher, Udatta
AU - Stanitsas, Panagiotis D.
AU - Hinrichs, James E.
AU - Kotsakis, Georgios A.
N1 - Publisher Copyright:
© 2014, Springer-Verlag Berlin Heidelberg.
PY - 2015/3
Y1 - 2015/3
N2 - Materials and methods: Implants were placed in patients exhibiting Seibert class I ridge defects resulting in peri-implant dehiscence defects. The defects were treated following GBR principles with the use of a CPS alloplastic bone graft putty in combination either with a collagen membrane or a titanium mesh. The height of each bony dehiscence was clinically measured at the time of implant placement and again during second-stage surgery. The percentage of complete defect coverage, frequency of adverse events, and risk factors for residual defect were determined.Results: Thirty-six implants were placed in 26 patients. Twenty-seven of the 36 sites employed a collagen membrane in conjunction with the CPS while the remaining nine sites utilized a titanium membrane. Mean gain in bone height was 3.23 ± 2.04 mm, with 75 % of the peri-implant defects achieving complete regeneration. A negative correlation was identified between patient age and complete coverage of the peri-implant defect (p = 0.026). The implant survival rate at 12 months was 97.22 %.Conclusion: Use of CPS bone putty during delayed implant placement at peri-implant dehiscence sites either in combination with a collagen membrane or a titanium mesh results in predictable defect coverage.Objectives: The purpose of this case series was to evaluate the new bone formation following guided bone regeneration (GBR) with a calcium phosphosilicate (CPS), alloplastic bone putty at peri-implant dehiscence defects and to assess survival rate of implants placed in the augmented sites after 12 months of function.Clinical relevance: The handling characteristics of CPS putty may simplify GBR protocol. Implants placed in conjunction with GBR have a very good survival rate after 1 year of follow-up.
AB - Materials and methods: Implants were placed in patients exhibiting Seibert class I ridge defects resulting in peri-implant dehiscence defects. The defects were treated following GBR principles with the use of a CPS alloplastic bone graft putty in combination either with a collagen membrane or a titanium mesh. The height of each bony dehiscence was clinically measured at the time of implant placement and again during second-stage surgery. The percentage of complete defect coverage, frequency of adverse events, and risk factors for residual defect were determined.Results: Thirty-six implants were placed in 26 patients. Twenty-seven of the 36 sites employed a collagen membrane in conjunction with the CPS while the remaining nine sites utilized a titanium membrane. Mean gain in bone height was 3.23 ± 2.04 mm, with 75 % of the peri-implant defects achieving complete regeneration. A negative correlation was identified between patient age and complete coverage of the peri-implant defect (p = 0.026). The implant survival rate at 12 months was 97.22 %.Conclusion: Use of CPS bone putty during delayed implant placement at peri-implant dehiscence sites either in combination with a collagen membrane or a titanium mesh results in predictable defect coverage.Objectives: The purpose of this case series was to evaluate the new bone formation following guided bone regeneration (GBR) with a calcium phosphosilicate (CPS), alloplastic bone putty at peri-implant dehiscence defects and to assess survival rate of implants placed in the augmented sites after 12 months of function.Clinical relevance: The handling characteristics of CPS putty may simplify GBR protocol. Implants placed in conjunction with GBR have a very good survival rate after 1 year of follow-up.
KW - Alloplastic bone putty
KW - Calcium phosphosilicate (CPS)
KW - Guided bone regeneration (GBR)
KW - Peri-implant dehiscence defects
UR - http://www.scopus.com/inward/record.url?scp=84939894810&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84939894810&partnerID=8YFLogxK
U2 - 10.1007/s00784-014-1268-4
DO - 10.1007/s00784-014-1268-4
M3 - Article
C2 - 24907860
AN - SCOPUS:84939894810
SN - 1432-6981
VL - 19
SP - 553
EP - 559
JO - Clinical Oral Investigations
JF - Clinical Oral Investigations
IS - 2
ER -